The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population

Experimental and Molecular Pathology

Volumn 91, Issue 2, 2011, Pages 622-625

  Belfki, Hanen ^a   Ben Ali, Samir ^a   Bougatef, Souha ^a   Ben Ahmed, Decy ^c   Haddad, Najet ^c   Jmal, Awatef ^b   Abdennebi, Monia ^b   Ben Romdhane, Habiba ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b Mahmoud El Matri Hospital of Ariana   (Tunisia)

^c Center of Basic Health Care of Ariana Essoghra   (Tunisia)

Author keywords

ApoA 1; ApoB; ApoB ApoA 1 ratio; Insulin resistance; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; TUNISIA; WAIST CIRCUMFERENCE;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; FEMALE; HUMANS; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUNISIA;

EID: 79961110345     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.06.007     Document Type: Article

References (20)

1. Boumaiza I., Omezzine A., Rejeb J., et al. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients. Metab. Syndr. Relat. Disord. 2010, 8:515-522.
2. Carnevale Schianca G.P., Pedrazzoli R., Onolfo S., et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 2011, 21:406-411.
3. Chan D.C., Watts G.F., Barrett P.H., O'Neill F.H., Thompson G.R. Plasma markers of cholesterol homeostasis and Apolipoprotein B-100 kinetics in the metabolic syndrome. Obes. Res. 2002, 11:591-596.
4. Elovson J., Chatterton J.E., Bell G.T., et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J. Lipid Res. 1988, 29:1461-1473.
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
6. Friedewald W.T., Levy R.T., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin. Chem. 1972, 18:449-502.
7. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
8. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular mortality in middle aged men. JAMA 2002, 288:2709-2716.
9. Lind L., Vessby B., Sundström J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler. Thromb. Vasc. Biol. 2006, 26:406-410.
10. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
11. Onat A., Can G., Hergenç G., Yazici M., Karabulut A., Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int. J. Obes. (Lond) 2007, 31:1119-1125.
12. Pont F., Duvillard L., Florentin E., Gambert P., Verges B. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int. J. Obes. Relat. Metab. Disord. 2002, 26:1151-1158.
13. Relimpio F., Losada F., Pumar A., Mangas M.A., Morales F., Astorga R. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2002, 57:199-207.
14. Sierra-Johnson J., Somers V.K., Kuniyoshi F.H., et al. Comparisonof apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am. J. Cardiol. 2006, 98:1369-1373.
15. Sierra-Johnson J., Fisher R.M., Romero-Corral A., et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur. Heart J. 2009, 30:710-717.
16. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777-780.
17. Thompson A., Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 2006, 259:481-492.
18. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J. Intern. Med. 2006, 259:493-519.
19. Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3years in middle-aged men. Stroke 2004, 35:2248-2252.
20. Zhang Y.L., Hernandez-Ono A., Ko C., Yasunaga K., Huang L.S., Ginsberg H.N. Regulation of hepatic Apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids: I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J. Biol. Chem. 2004, 279:19362-19374.